Holen Sie sich die Stockscreener-App
17.74
1.44%
-0.26
Handel nachbörslich:
17.75
0.01
+0.06%
Schlusskurs vom Vortag:
$18.00
Offen:
$18.01
24-Stunden-Volumen:
285.72K
Relative Volume:
0.55
Marktkapitalisierung:
$6.25B
Einnahmen:
$4.68B
Nettoeinkommen (Verlust:
$-368.00M
KGV:
-16.90
EPS:
-1.05
Netto-Cashflow:
$-58.00M
1W Leistung:
-1.28%
1M Leistung:
-9.81%
6M Leistung:
+21.01%
1J Leistung:
+8.24%
1-Tages-Spanne:
$17.72
$18.10
1-Wochen-Bereich:
$17.63
$18.55
52-Wochen-Spanne:
$13.16
$21.69
Bausch Lomb Corp Stock (BLCO) Company Profile
Firmenname
Bausch Lomb Corp
Sektor
Telefon
908-541-5456
Adresse
520 APPLEWOOD CRESCENT, VAUGHAN
Vergleichen Sie BLCO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
17.74 | 6.25B | 4.68B | -368.00M | -58.00M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
535.29 | 190.66B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
228.46 | 66.26B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
84.06 | 41.58B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
231.67 | 34.01B | 4.81B | 1.11B | 1.35B | 7.55 |
|
WST
West Pharmaceutical Services Inc
|
335.56 | 24.30B | 2.88B | 499.60M | 321.60M | 6.74 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-07-10 | Eingeleitet | Raymond James | Outperform |
| 2024-05-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-12 | Eingeleitet | Stifel | Hold |
| 2023-10-03 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-09 | Eingeleitet | Needham | Hold |
| 2022-12-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-06-24 | Eingeleitet | Evercore ISI | Outperform |
| 2022-06-06 | Eingeleitet | Citigroup | Buy |
| 2022-05-31 | Eingeleitet | Deutsche Bank | Hold |
| 2022-05-31 | Eingeleitet | Goldman | Neutral |
| 2022-05-31 | Eingeleitet | Guggenheim | Buy |
| 2022-05-31 | Eingeleitet | JP Morgan | Neutral |
| 2022-05-31 | Eingeleitet | Jefferies | Buy |
| 2022-05-31 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-05-11 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Bausch Lomb Corp Aktie (BLCO) Neueste Nachrichten
Bausch + Lomb Corporation - Baystreet.ca
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Ocular Prosthesis Market Trends, Challenges and Opportunities to 2030: A Projected $2.3 Billion Landscape - GlobeNewswire Inc.
Aesthetic Ophthalmology Devices Business Analysis Report 2024-2030 Featuring 40+ Key Players Including Abbott, Bausch & Lomb, Alcon, Allergan, Carl Zeiss, Haag Streit, Meditec, Topcon, Zeimer - Yahoo Finance
Bausch + Lomb down after report that Blackstone could back away from takeover bid - MSN
BofA rates Bausch & Lomb ‘underperform’ with lower buyout chances - MSN
Y Intercept Hong Kong Ltd Makes New Investment in Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Short Interest in Bausch + Lomb Co. (NYSE:BLCO) Rises By 11.7% - MarketBeat
Janus Henderson Group PLC Purchases New Shares in Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Bausch And Lomb Says Potential Sale In The Works - Law360
Bausch + Lomb exploring several options including a potential sale - Coast Reporter
Contact lens maker Bausch + Lomb says it is exploring sale - Reuters
Bausch + Lomb confirms it is exploring a potential sale - Financial Post
Bausch + Lomb responds to rumors of potential sale - Rochester Business Journal
Bausch + Lomb explores potential sale amid market rumors - Investing.com
Bausch + Lomb confirms board mulling sale of the company that would separate it from parent - MarketWatch
Bausch + Lomb explores sale amid separation plans - Investing.com
Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb - Jonesboro Sun
Bausch + Lomb Responds to Rumors of a Potential Sale - Business Wire
Eye health company Bausch + Lomb’s affiliate acquires Elios Vision - Yahoo Finance
Bausch & Lomb: Key Partner in Joint Takeover's Interest Reportedly Cools, Spooking Investors - Morningstar
King Street Capital Management L.P. Buys New Stake in Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Bausch + Lomb acquires glaucoma surgery innovator - Investing.com
S&P 500 Futures Rise in Premarket Trading; Bausch + Lomb, Bio-Techne Lag - Barron's
Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities - Business Wire
Quadrature Capital Ltd Takes Position in Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Finanzdaten der Bausch Lomb Corp-Aktie (BLCO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):